References
1. Williams, B., et al., 2018
ESC/ESH Guidelines for the management of arterial hypertension. Eur
Heart J, 2018. 39 (33): p. 3021-3104.
2. China, T.W.C.o.t.R.o.C.H.D.i.,Annual report on cardiovascular health and diseases in China
2019. Chinese Circulation Journal, 2020. 35 (09): p. 833-854.
3. Wang, Z., et al., Status of
Hypertension in China: Results From the China Hypertension Survey,
2012-2015. Circulation, 2018. 137 (22): p. 2344-2356.
4. Joint Committee for Guideline, R.,2018 Chinese Guidelines for Prevention and Treatment of
Hypertension-A report of the Revision Committee of Chinese Guidelines
for Prevention and Treatment of Hypertension. J Geriatr Cardiol, 2019.16 (3): p. 182-241.
5. Canbakan, B., Rational
approaches to the treatment of hypertension: drug therapy-monotherapy,
combination, or fixed-dose combination? Kidney Int Suppl (2011), 2013.3 (4): p. 349-351.
6. Brunner, D.B., et al., Effect
of a new angiotensin converting enzyme inhibitor MK 421 and its lysine
analogue on the components of the renin system in healthy subjects. Br
J Clin Pharmacol, 1981. 11 (5): p. 461-7.
7. Song, J.C. and C.M. White,Clinical pharmacokinetics and selective pharmacodynamics of new
angiotensin converting enzyme inhibitors: an update. Clin
Pharmacokinet, 2002. 41 (3): p. 207-24.
8. Beermann, B., et al.,Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers.Biopharm Drug Dispos, 1989. 10 (4): p. 397-409.
9. Zhu, Y., et al., Amlodipine
metabolism in human liver microsomes and roles of CYP3A4/5 in the
dihydropyridine dehydrogenation. Drug Metab Dispos, 2014.42 (2): p. 245-9.
10. Li, X., et al.,Bioequivalence of levamlodipine besylate tablets in healthy
Chinese subjects: a single-dose and two-period crossover randomized
study. BMC Pharmacol Toxicol, 2020. 21 (1): p. 80.
11. Naidu, M.U., et al.,Evaluation of amlodipine, lisinopril, and a combination in the
treatment of essential hypertension. Postgrad Med J, 2000.76 (896): p. 350-3.
12. Galeeva, Z.M. and A.S. Galiavich,[A fixed-dose lisinopril and amlodipine combination in
conjunction with rosuvastatin in patients with hypertensive disease and
coronary heart disease]. Ter Arkh, 2014. 86 (9): p. 71-6.
13. Tamimi, J.J., et al.,Bioequivalence evaluation of two brands of lisinopril tablets
(Lisotec and Zestril) in healthy human volunteers. Biopharm Drug
Dispos, 2005. 26 (8): p. 335-9.
14. Georgarakis, M., et al.,Evaluation of the bioequivalence and pharmacokinetics of two
lisinopril tablet formulations after single oral administration in
healthy volunteers. Arzneimittelforschung, 2004. 54 (1): p.
15-9.
15. Shin, M.C., J.K. Kim, and C.K.
Kim, Bioequivalence evaluation of two brands of lisinopril tablets
by in vitro comparative dissolution test and in vivo bioequivalence
test. Arzneimittelforschung, 2008. 58 (1): p. 11-7.
16. Mojaverian, P., et al.,Effect of food on the bioavailability of lisinopril, a
nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci,
1986. 75 (4): p. 395-7.
17. Deng, J., et al., A Review
of Food-Drug Interactions on Oral Drug Absorption. Drugs, 2017.77 (17): p. 1833-1855.
18. Berg, W., [Metabolism and
pathophysiology of oxalic acid]. Z Urol Nephrol, 1990.83 (9): p. 481-8.
19. Thind, G.S., Angiotensin
converting enzyme inhibitors: comparative structure, pharmacokinetics,
and pharmacodynamics. Cardiovasc Drugs Ther, 1990. 4 (1): p.
199-206.
20. Lecocq, B., et al.,Influence of food on the pharmacokinetics of perindopril and the
time course of angiotensin-converting enzyme inhibition in serum. Clin
Pharmacol Ther, 1990. 47 (3): p. 397-402.
21. Wu, C.Y. and L.Z. Benet,Predicting drug disposition via application of BCS:
transport/absorption/ elimination interplay and development of a
biopharmaceutics drug disposition classification system. Pharm Res,
2005. 22 (1): p. 11-23.
22. Ulm, E.H., et al.,Enalapril maleate and a lysine analogue (MK-521): disposition in
man. Br J Clin Pharmacol, 1982. 14 (3): p. 357-62.
23. Vandenburg, M.J., et al., A
study of the potential pharmacokinetic interaction of lisinopril and
digoxin in normal volunteers. Xenobiotica, 1988. 18 (10): p.
1179-84.
24. Lees, K.R. and J.L. Reid,Lisinopril and nifedipine: no acute interaction in normotensives.Br J Clin Pharmacol, 1988. 25 (3): p. 307-13.
25. Koytchev, R., et al.,Effect of the combination of lisinopril and hydrochlorothiazide on
the bioequivalence of tablet formulations. Arzneimittelforschung, 2004.54 (9A): p. 605-10.
26. Gautam, P.C., E. Vargas, and M.
Lye, Pharmacokinetics of lisinopril (MK521) in healthy young and
elderly subjects and in elderly patients with cardiac failure. J Pharm
Pharmacol, 1987. 39 (11): p. 929-31.
27. Misaka, S., et al., Impact
of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in
Healthy Volunteers. Clin Transl Sci, 2021. 14 (2): p. 476-480.